Inferra AI / Company / CRL
Charles River Laboratories
CRL · Health Care
Last earnings Aug 5, 2026
Key results
Second-Quarter revenuequarter
$1.03
Second-Quarter Revenue of $1.03
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Billion Second-Quarter EPSquarter
$1.06
Billion Second-Quarter GAAP Earnings per Share of $1.06 and
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
EPSquarter
$3.12
Non-GAAP Earnings per Share of $3.12
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Revenuequarter
$1,032.1 million
For the quarter, revenue was $1,032.1 million, an increase of 0.6% from $1,026.1 million in the second quarter of 2024.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
The impact of foreign currency translation increased reported revenue by 1.2%.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Excluding this impact, revenue declined 0.5% on an organic basis.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
GAAP operating marginquarter
9.7%
In the second quarter of 2025, the GAAP operating margin decreased to 9.7% from 14.8% in the second quarter of 2024.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
GAAP net incomequarter
$52.3 million
GAAP net income available to common shareholders for the second quarter of 2025 was $52.3 million, or $1.06 per share, a decrease from net earnings of $90.0 million, or $1.74 per diluted share, for the same period in 2024.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Net incomequarter
$90.0 million
GAAP net income available to common shareholders for the second quarter of 2025 was $52.3 million, or $1.06 per share, a decrease from net earnings of $90.0 million, or $1.74 per diluted share, for the same period in 2024.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Selling, general, and administrativequarter
$191,549 thousand
Selling, general and administrative 191,549 169,791 369,348 356,082
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Operating incomequarter
$100,134 thousand
Operating income 100,134 151,652 174,803 277,629
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
AI analysis
Q2 2025 · reported Aug 6, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Second-Quarter revenue | $1.03 | — | — |
| Billion Second-Quarter EPS | $1.06 | — | — |
| EPS | $3.12 | — | — |
| Revenue | $1,032.1 million | — | — |
| GAAP operating margin | 9.7% | — | — |
| GAAP net income | $52.3 million | — | — |
| Net income | $90.0 million | — | — |
| Selling, general, and administrative | $191,549 thousand | — | — |
Guidance · company-stated
Direction: Raised
“The Company is increasing its full-year outlook for revenue and non-GAAP earnings per share to primarily reflect better-than-expected second-quarter financial results, particularly in the DSA segment, and to a lesser extent, a more favorable impact from foreign exchange.”
Classified from the release's primary full-year outlook statement.
Margin
Capital allocation
In addition, lower diluted shares outstanding due to the Company's stock repurchase program also contributed to the increase in non-GAAP earnings per share.
$ 52,326 $ 94,081 $ 77,795 $ 167,041 Less Adjustment of redeemable noncontrolling interest 301 702 Less Incremental dividends attributed to noncontrolling interest holders 3,792 9,022 Net income available to Charles River Laboratories International, Inc.
Event summary
CHARLES RIVER LABORATORIES ANNOUNCES SECOND-QUARTER 2025 RESULTS
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue — Raised (“increasing”)
“The Company is increasing its full-year outlook for revenue and non-GAAP earnings per share to primarily reflect better-than-expected second-quarter financial results, particularly in the DSA segment, and to a lesser extent, a more favorable impact from foreign exchange.”
Classified from the release's primary full-year outlook statement.
Capital allocation
In addition, lower diluted shares outstanding due to the Company's stock repurchase program also contributed to the increase in non-GAAP earnings per share.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
$ 52,326 $ 94,081 $ 77,795 $ 167,041 Less Adjustment of redeemable noncontrolling interest 301 702 Less Incremental dividends attributed to noncontrolling interest holders 3,792 9,022 Net income available to Charles River Laboratories International, Inc.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
common shareholders $ 52,326 $ 89,988 $ 77,795 $ 157,317 Add back Adjustment of redeemable noncontrolling interest (2) 301 702 Incremental dividends attributable to noncontrolling interest holders (3) 3,792 9,022 Non-GAAP adjustments to operating income (4) 127,079 65,576 239,472 127,017 Venture capital and strategic equity investment (gains) losses, net 1,424 (902) 11,393 (6,664) (Gain) loss on divestitures (5) (3,376) 658 Tax effect of non-GAAP adjustments Non-cash tax provision related to international financing structure (6) 871 1,212 Tax effect of the remaining non-GAAP adjustments (26,837) (14,687) (52,182) (26,715) Net income available to Charles River Laboratories International, Inc.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
(3) This amount represents incremental declared and undeclared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
The acquisition was funded through a combination of cash on hand and borrowings under the Credit Facility.
SEC original ↗Charles River Laboratories — 10-Q Quarterly report10-QAug 5, 2026
The acquisition was funded through a combination of available cash and proceeds from the Company s Credit Facility.
SEC original ↗Charles River Laboratories — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
The GAAP and non-GAAP operating margin increases were primarily driven by the favorable revenue mix related to large research models and operating leverage from higher revenue for research models services, as well as the benefit of cost savings resulting from the Company's restructuring initiatives.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
The GAAP operating margin decline was primarily driven by lower revenue, higher costs associated with the Company's restructuring initiatives, and higher third-party legal costs related to U.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
The non-GAAP operating margin increase was primarily driven by the benefit of cost savings resulting from the Company's restructuring initiatives, partially offset by lower revenue.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
(4) Certain venture capital and other strategic investment performance only includes recognized gains or losses on certain investments.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Risks & headwinds
We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Forward-looking statements are based on Charles River s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Those risks and uncertainties include, but are not limited to NHP supply constraints and the investigations by the U.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 19, 2025, as well as other filings we make with the Securities and Exchange Commission.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.
SEC original ↗Charles River Laboratories — Earnings release (8-K exhibit)EX-99Aug 6, 2025
These statements are based on our current expectations and beliefs and involve a number of risks, uncertainties and assumptions that are difficult to predict.
SEC original ↗Charles River Laboratories — 10-Q Quarterly report10-QAug 5, 2026
Earnings deck slides
0 decks with slide viewCharles River Laboratories — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documents- Q2 2026
- 8-KCRL
Sep 24, 2026
- 10-QCRL
- 8-KCRL
- Q1 2026
- 8-KCRL
May 11, 2026
- 10-QCRL
- 8-KCRL
- Q4 2025
- 8-KCRL
Feb 25, 2026
- 8-KCRL
Feb 18, 2026
- 10-KCRL
Feb 18, 2026
- 8-KCRL
Feb 18, 2026
- 8-KCRL
Jan 13, 2026
- 8-KCRL
- Q3 2025
- 8-KCRL
- 8-KCRL
Nov 17, 2025
- 10-QCRL
- 8-KCRL
- Q2 2025
- 8-K/ACRL
- 8-KCRL
Sep 16, 2025
- 10-QCRL
- 8-KCRL
- Q1 2025
- 8-KCRL
May 23, 2025
- 10-QCRL
- 8-KCRL
- 8-KCRL
- Q4 2024
- 8-KCRL
Feb 21, 2025
- 10-KCRL
Feb 19, 2025
- 8-KCRL
Feb 19, 2025
- 8-KCRL
Jan 14, 2025
- Q3 2024
- 8-KCRL
Dec 13, 2024
- 10-QCRL
Earnings releases
7 documentsPresentations
1 document- Q2 2026
- CRLDeck
Transcripts
0 documentsNo transcripts for Charles River Laboratories are held in this edition of the library.
Mentioned by
2 companiesOther tracked companies whose held documents mention Charles River Laboratories by name or ticker. A mention is counted once per document, from the document text the library holds.
“r Share Expected at the Upper Ends of Prior Ranges – WILMINGTON, MA, September 24, 2026 – Charles River Laboratories… … Client Experience – – Issues Long-Term Financial Targets through 2030 – – Reaffirms 2026 Financial Guidance with Revenue and Non-G”
“2) Purchases of investments and contributions to venture capital investments (11,805)… …CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SCHEDULE 3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands) Six Months Ende”
See also the earnings calendar for every tracked company’s next earnings date.